In fact, the clinical efficacy of BTK inhibitors in GvHD (Jaglowski and Blazar, 2018) and COVID-19, and the reported role of the NLRP3/IL-1 axis in these disease states (Jankovic et al., 2013; Roschewski et al., 2020) lend support to the notion that BTK-inhibitor therapy for NLRP3 inhibition warrants further preclinical and clinical exploration. Here, NLRP3 is linked to COVID-19.